Serous carcinoma of the ovary - Revision history

Michael at 16:16, 4 November 2024

2024-11-04T16:16:23Z

← Older revision		Revision as of 16:16, 4 November 2024
Line 7:		Line 7:
	\| Micro =		\| Micro =
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[serous carcinoma]] from other sites, [[clear cell carcinoma of the ovary]], poorly differentiated [[endometrioid carcinoma of the ovary]], [[ovarian serous borderline tumour]] for low-grade tumours		\| LMDDx = [[serous carcinoma]] from other sites (e.g. [[serous carcinoma of the fallopian tube]]), [[clear cell carcinoma of the ovary]], poorly differentiated [[endometrioid carcinoma of the ovary]], [[ovarian serous borderline tumour]] for low-grade tumours
	\| Stains =		\| Stains =
	\| IHC = WT-1 +ve, CK7 +ve, ER +ve, [[HNF-1beta]] -ve		\| IHC = WT-1 +ve, CK7 +ve, ER +ve, [[HNF-1beta]] -ve

Michael at 05:13, 4 November 2024

2024-11-04T05:13:00Z

← Older revision		Revision as of 05:13, 4 November 2024
Line 153:		Line 153:
	*[[Ovary]].		*[[Ovary]].
	*[[Ovarian tumours]].		*[[Ovarian tumours]].
			*[[Serous carcinoma of the fallopian tube]].

	==References==		==References==

Michael at 21:27, 2 July 2020

2020-07-02T21:27:28Z

← Older revision		Revision as of 21:27, 2 July 2020
Line 9:		Line 9:
	\| LMDDx = [[serous carcinoma]] from other sites, [[clear cell carcinoma of the ovary]], poorly differentiated [[endometrioid carcinoma of the ovary]], [[ovarian serous borderline tumour]] for low-grade tumours		\| LMDDx = [[serous carcinoma]] from other sites, [[clear cell carcinoma of the ovary]], poorly differentiated [[endometrioid carcinoma of the ovary]], [[ovarian serous borderline tumour]] for low-grade tumours
	\| Stains =		\| Stains =
	\| IHC = WT-1 +ve, CK7 +ve, ER +ve, HNF-1beta -ve		\| IHC = WT-1 +ve, CK7 +ve, ER +ve, [[HNF-1beta]] -ve
	\| EM =		\| EM =
	\| Molecular = +/-BRCA1 mutation, +/-BRCA2 mutation		\| Molecular = +/-BRCA1 mutation, +/-BRCA2 mutation

Michael: /* IHC */

2016-06-06T13:50:32Z

IHC

← Older revision		Revision as of 13:50, 6 June 2016
Line 107:		Line 107:

	==IHC==		==IHC==
	*WT-1 +ve - '''key immunostain'''.<ref name=pmid18830127>{{Cite journal \| last1 = Köbel \| first1 = M. \| last2 = Kalloger \| first2 = SE. \| last3 = Carrick \| first3 = J. \| last4 = Huntsman \| first4 = D. \| last5 = Asad \| first5 = H. \| last6 = Oliva \| first6 = E. \| last7 = Ewanowich \| first7 = CA. \| last8 = Soslow \| first8 = RA. \| last9 = Gilks \| first9 = CB. \| title = A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. \| journal = Am J Surg Pathol \| volume = 33 \| issue = 1 \| pages = 14-21 \| month = Jan \| year = 2009 \| doi = 10.1097/PAS.0b013e3181788546 \| PMID = 18830127 }}</ref>		*[[WT-1]] +ve - '''key immunostain'''.<ref name=pmid18830127>{{Cite journal \| last1 = Köbel \| first1 = M. \| last2 = Kalloger \| first2 = SE. \| last3 = Carrick \| first3 = J. \| last4 = Huntsman \| first4 = D. \| last5 = Asad \| first5 = H. \| last6 = Oliva \| first6 = E. \| last7 = Ewanowich \| first7 = CA. \| last8 = Soslow \| first8 = RA. \| last9 = Gilks \| first9 = CB. \| title = A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. \| journal = Am J Surg Pathol \| volume = 33 \| issue = 1 \| pages = 14-21 \| month = Jan \| year = 2009 \| doi = 10.1097/PAS.0b013e3181788546 \| PMID = 18830127 }}</ref>
	*CK7 +ve.		*[[CK7]] +ve.
	*CA-125 +ve.		*CA-125 +ve.
	*ER +ve.<ref name=pmid21164285>{{Cite journal \| last1 = DeLair \| first1 = D. \| last2 = Oliva \| first2 = E. \| last3 = Köbel \| first3 = M. \| last4 = Macias \| first4 = A. \| last5 = Gilks \| first5 = CB. \| last6 = Soslow \| first6 = RA. \| title = Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 1 \| pages = 36-44 \| month = Jan \| year = 2011 \| doi = 10.1097/PAS.0b013e3181ff400e \| PMID = 21164285 }}</ref>		*ER +ve.<ref name=pmid21164285>{{Cite journal \| last1 = DeLair \| first1 = D. \| last2 = Oliva \| first2 = E. \| last3 = Köbel \| first3 = M. \| last4 = Macias \| first4 = A. \| last5 = Gilks \| first5 = CB. \| last6 = Soslow \| first6 = RA. \| title = Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 1 \| pages = 36-44 \| month = Jan \| year = 2011 \| doi = 10.1097/PAS.0b013e3181ff400e \| PMID = 21164285 }}</ref>

Michael: /* General */

2016-03-13T21:26:06Z

General

← Older revision		Revision as of 21:26, 13 March 2016
Line 40:		Line 40:
	Precursors lesions:		Precursors lesions:
	*[[Serous borderline tumour]]s for low-grade serious carcinoma.		*[[Serous borderline tumour]]s for low-grade serious carcinoma.
			**Generally do not progress to high-grade serous carcinoma.{{fact}}
	*[[Serous tubal intraepithelial carcinoma]] (STIC)<ref name=pmid23240669>{{Cite journal \| last1 = Vang \| first1 = R. \| last2 = Shih \| first2 = IeM. \| last3 = Kurman \| first3 = RJ. \| title = Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. \| journal = Histopathology \| volume = 62 \| issue = 1 \| pages = 44-58 \| month = Jan \| year = 2013 \| doi = 10.1111/his.12046 \| PMID = 23240669 }}</ref> for high-grade serous carcinoma.		*[[Serous tubal intraepithelial carcinoma]] (STIC)<ref name=pmid23240669>{{Cite journal \| last1 = Vang \| first1 = R. \| last2 = Shih \| first2 = IeM. \| last3 = Kurman \| first3 = RJ. \| title = Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. \| journal = Histopathology \| volume = 62 \| issue = 1 \| pages = 44-58 \| month = Jan \| year = 2013 \| doi = 10.1111/his.12046 \| PMID = 23240669 }}</ref> for high-grade serous carcinoma.

Michael: /* Sign out */ fix sp

2016-03-13T21:25:07Z

Sign out: fix sp

← Older revision		Revision as of 21:25, 13 March 2016
Line 144:		Line 144:
	the primary site of this serous carcinoma.		the primary site of this serous carcinoma.

	High-grade serous carcinoma of ovary/~~fallopain~~ tube/periteonum is associated		High-grade serous carcinoma of ovary/fallopian tube/periteonum is associated
	with BRCA1/2 mutation in approximately 20% of patients. Referral to genetic		with BRCA1/2 mutation in approximately 20% of patients. Referral to genetic
	~~counselling~~ is recommended.		counseling is recommended.
	</pre>		</pre>

Michael: /* Sign out */

2016-03-13T21:22:05Z

Sign out

← Older revision		Revision as of 21:22, 13 March 2016
Line 143:		Line 143:
	Clinical and radiologic correlation is suggested for the determination of		Clinical and radiologic correlation is suggested for the determination of
	the primary site of this serous carcinoma.		the primary site of this serous carcinoma.

			High-grade serous carcinoma of ovary/fallopain tube/periteonum is associated
			with BRCA1/2 mutation in approximately 20% of patients. Referral to genetic
			counselling is recommended.
	</pre>		</pre>

Michael: /* General */

2016-03-13T21:19:41Z

General

← Older revision		Revision as of 21:19, 13 March 2016
Line 36:		Line 36:
	*Poor prognosis.		*Poor prognosis.
	*May be associated with a ''[[BRCA1]] gene'' or ''[[BRCA2]] gene'' mutation.<ref name=pmid23707676>{{Cite journal \| last1 = Demsky \| first1 = R. \| last2 = McCuaig \| first2 = J. \| last3 = Maganti \| first3 = M. \| last4 = Murphy \| first4 = KJ. \| last5 = Rosen \| first5 = B. \| last6 = Armel \| first6 = SR. \| title = Keeping it simple: genetics referrals for all invasive serous ovarian cancers. \| journal = Gynecol Oncol \| volume = 130 \| issue = 2 \| pages = 329-33 \| month = Aug \| year = 2013 \| doi = 10.1016/j.ygyno.2013.05.003 \| PMID = 23707676 }}</ref>		*May be associated with a ''[[BRCA1]] gene'' or ''[[BRCA2]] gene'' mutation.<ref name=pmid23707676>{{Cite journal \| last1 = Demsky \| first1 = R. \| last2 = McCuaig \| first2 = J. \| last3 = Maganti \| first3 = M. \| last4 = Murphy \| first4 = KJ. \| last5 = Rosen \| first5 = B. \| last6 = Armel \| first6 = SR. \| title = Keeping it simple: genetics referrals for all invasive serous ovarian cancers. \| journal = Gynecol Oncol \| volume = 130 \| issue = 2 \| pages = 329-33 \| month = Aug \| year = 2013 \| doi = 10.1016/j.ygyno.2013.05.003 \| PMID = 23707676 }}</ref>
	**Approximately 20% of high-grade serous carcinoma are associated with BRCA1 or BRCA2.<ref ~~name22776961~~>{{Cite journal \| last1 = Schrader \| first1 = KA. \| last2 = Hurlburt \| first2 = J. \| last3 = Kalloger \| first3 = SE. \| last4 = Hansford \| first4 = S. \| last5 = Young \| first5 = S. \| last6 = Huntsman \| first6 = DG. \| last7 = Gilks \| first7 = CB. \| last8 = McAlpine \| first8 = JN. \| title = Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. \| journal = Obstet Gynecol \| volume = 120 \| issue = 2 Pt 1 \| pages = 235-40 \| month = Aug \| year = 2012 \| doi = 10.1097/AOG.0b013e31825f3576 \| PMID = 22776961 }}</ref>		**Approximately 20% of high-grade serous carcinoma are associated with BRCA1 or BRCA2.<ref name=pmid22776961>{{Cite journal \| last1 = Schrader \| first1 = KA. \| last2 = Hurlburt \| first2 = J. \| last3 = Kalloger \| first3 = SE. \| last4 = Hansford \| first4 = S. \| last5 = Young \| first5 = S. \| last6 = Huntsman \| first6 = DG. \| last7 = Gilks \| first7 = CB. \| last8 = McAlpine \| first8 = JN. \| title = Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. \| journal = Obstet Gynecol \| volume = 120 \| issue = 2 Pt 1 \| pages = 235-40 \| month = Aug \| year = 2012 \| doi = 10.1097/AOG.0b013e31825f3576 \| PMID = 22776961 }}</ref>

	Precursors lesions:		Precursors lesions:

Michael: /* General */

2016-03-13T21:19:22Z

General

← Older revision		Revision as of 21:19, 13 March 2016
Line 36:		Line 36:
	*Poor prognosis.		*Poor prognosis.
	*May be associated with a ''[[BRCA1]] gene'' or ''[[BRCA2]] gene'' mutation.<ref name=pmid23707676>{{Cite journal \| last1 = Demsky \| first1 = R. \| last2 = McCuaig \| first2 = J. \| last3 = Maganti \| first3 = M. \| last4 = Murphy \| first4 = KJ. \| last5 = Rosen \| first5 = B. \| last6 = Armel \| first6 = SR. \| title = Keeping it simple: genetics referrals for all invasive serous ovarian cancers. \| journal = Gynecol Oncol \| volume = 130 \| issue = 2 \| pages = 329-33 \| month = Aug \| year = 2013 \| doi = 10.1016/j.ygyno.2013.05.003 \| PMID = 23707676 }}</ref>		*May be associated with a ''[[BRCA1]] gene'' or ''[[BRCA2]] gene'' mutation.<ref name=pmid23707676>{{Cite journal \| last1 = Demsky \| first1 = R. \| last2 = McCuaig \| first2 = J. \| last3 = Maganti \| first3 = M. \| last4 = Murphy \| first4 = KJ. \| last5 = Rosen \| first5 = B. \| last6 = Armel \| first6 = SR. \| title = Keeping it simple: genetics referrals for all invasive serous ovarian cancers. \| journal = Gynecol Oncol \| volume = 130 \| issue = 2 \| pages = 329-33 \| month = Aug \| year = 2013 \| doi = 10.1016/j.ygyno.2013.05.003 \| PMID = 23707676 }}</ref>
			**Approximately 20% of high-grade serous carcinoma are associated with BRCA1 or BRCA2.<ref name22776961>{{Cite journal \| last1 = Schrader \| first1 = KA. \| last2 = Hurlburt \| first2 = J. \| last3 = Kalloger \| first3 = SE. \| last4 = Hansford \| first4 = S. \| last5 = Young \| first5 = S. \| last6 = Huntsman \| first6 = DG. \| last7 = Gilks \| first7 = CB. \| last8 = McAlpine \| first8 = JN. \| title = Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. \| journal = Obstet Gynecol \| volume = 120 \| issue = 2 Pt 1 \| pages = 235-40 \| month = Aug \| year = 2012 \| doi = 10.1097/AOG.0b013e31825f3576 \| PMID = 22776961 }}</ref>

	Precursors lesions:		Precursors lesions:

Michael: /* General */

2014-07-15T20:14:16Z

General

← Older revision		Revision as of 20:14, 15 July 2014
Line 35:		Line 35:
	*Most common malignant ovarian tumour in the eldery.		*Most common malignant ovarian tumour in the eldery.
	*Poor prognosis.		*Poor prognosis.
	*May be associated with a ''[[BRCA1]] gene'' or ''[[~~BRACA2~~]] gene'' mutation.<ref name=pmid23707676>{{Cite journal \| last1 = Demsky \| first1 = R. \| last2 = McCuaig \| first2 = J. \| last3 = Maganti \| first3 = M. \| last4 = Murphy \| first4 = KJ. \| last5 = Rosen \| first5 = B. \| last6 = Armel \| first6 = SR. \| title = Keeping it simple: genetics referrals for all invasive serous ovarian cancers. \| journal = Gynecol Oncol \| volume = 130 \| issue = 2 \| pages = 329-33 \| month = Aug \| year = 2013 \| doi = 10.1016/j.ygyno.2013.05.003 \| PMID = 23707676 }}</ref>		*May be associated with a ''[[BRCA1]] gene'' or ''[[BRCA2]] gene'' mutation.<ref name=pmid23707676>{{Cite journal \| last1 = Demsky \| first1 = R. \| last2 = McCuaig \| first2 = J. \| last3 = Maganti \| first3 = M. \| last4 = Murphy \| first4 = KJ. \| last5 = Rosen \| first5 = B. \| last6 = Armel \| first6 = SR. \| title = Keeping it simple: genetics referrals for all invasive serous ovarian cancers. \| journal = Gynecol Oncol \| volume = 130 \| issue = 2 \| pages = 329-33 \| month = Aug \| year = 2013 \| doi = 10.1016/j.ygyno.2013.05.003 \| PMID = 23707676 }}</ref>

	Precursors lesions:		Precursors lesions: